These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36419768)

  • 1. JMJD6 orchestrates a transcriptional program in favor of endocrine resistance in ER+ breast cancer cells.
    Das P; Gupta A; Desai KV
    Front Endocrinol (Lausanne); 2022; 13():1028616. PubMed ID: 36419768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.
    Lee YF; Miller LD; Chan XB; Black MA; Pang B; Ong CW; Salto-Tellez M; Liu ET; Desai KV
    Breast Cancer Res; 2012 May; 14(3):R85. PubMed ID: 22621393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
    Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
    Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.
    Moerkens M; Zhang Y; Wester L; van de Water B; Meerman JH
    BMC Cancer; 2014 Apr; 14():283. PubMed ID: 24758408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
    Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
    Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JMJD6 induces HOTAIR, an oncogenic lincRNA, by physically interacting with its proximal promoter.
    Biswas A; Shettar A; Mukherjee G; Kondaiah P; Desai KV
    Biochem J; 2018 Jan; 475(1):355-371. PubMed ID: 29229759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JMJD6 Licenses ERα-Dependent Enhancer and Coding Gene Activation by Modulating the Recruitment of the CARM1/MED12 Co-activator Complex.
    Gao WW; Xiao RQ; Zhang WJ; Hu YR; Peng BL; Li WJ; He YH; Shen HF; Ding JC; Huang QX; Ye TY; Li Y; Liu ZY; Ding R; Rosenfeld MG; Liu W
    Mol Cell; 2018 Apr; 70(2):340-357.e8. PubMed ID: 29628309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer.
    Biswas A; Mukherjee G; Kondaiah P; Desai KV
    BMC Cancer; 2020 Nov; 20(1):1159. PubMed ID: 33246425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis.
    Lu C; Yang Y; Lingmei L; Qiujuan H; Qianru G; Lisha Q; Wenfeng C; Yun N; Peisen Z
    Breast Cancer Res Treat; 2023 Jan; 197(1):71-82. PubMed ID: 36334189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
    Xiong H; Jin X; You C
    Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer.
    Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L
    Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JMJD6 regulates ERα methylation on arginine.
    Poulard C; Rambaud J; Hussein N; Corbo L; Le Romancer M
    PLoS One; 2014; 9(2):e87982. PubMed ID: 24498420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.
    Johmura Y; Maeda I; Suzuki N; Wu W; Goda A; Morita M; Yamaguchi K; Yamamoto M; Nagasawa S; Kojima Y; Tsugawa K; Inoue N; Miyoshi Y; Osako T; Akiyama F; Maruyama R; Inoue JI; Furukawa Y; Ohta T; Nakanishi M
    J Clin Invest; 2018 Dec; 128(12):5603-5619. PubMed ID: 30418174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
    Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
    Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
    Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
    Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.